PE20240928A1 - Derivados de triazina y su uso en el tratamiento del cancer - Google Patents
Derivados de triazina y su uso en el tratamiento del cancerInfo
- Publication number
- PE20240928A1 PE20240928A1 PE2023003133A PE2023003133A PE20240928A1 PE 20240928 A1 PE20240928 A1 PE 20240928A1 PE 2023003133 A PE2023003133 A PE 2023003133A PE 2023003133 A PE2023003133 A PE 2023003133A PE 20240928 A1 PE20240928 A1 PE 20240928A1
- Authority
- PE
- Peru
- Prior art keywords
- halo
- alkyl
- compounds
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invencion se refiere a compuestos que tienen la formula general lb, una composicion que incluye los compuestos y metodos para usar los compuestos en el tratamiento del cancer. En particular, la invencion se refiere a compuestos de formula Ib en donde R1 es H, halo, alquilo, entre otros; R5 es H; o R1 y R5, y los atomos a los que estan unidos, forman: o un anillo de heterociclo de 4-6 miembros que comprende un unico heteroatomo de O o un anillo de cicloalquilo de 3-6 miembros, opcionalmente sustituido con uno o dos sustituyentes seleccionados independientemente de halo o alquilo; R2 es H, halo, alquilo, haloalquilo, entre otros; R3 es H, alquilo, haloalquilo o cicloalquilo opcionalmente sustituido con halo; Z es -O-, -NH- o -NHCH2-; R4 es un anillo de heterociclo o cicloalquilo opcionalmente sustituido con 1 a 2 o 1 a 3 sustituyentes respectivamente seleccionados independientemente de halo, alquilo, haloalquilo, entre otros.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21177660 | 2021-06-04 | ||
| EP21188639 | 2021-07-30 | ||
| EP21215875 | 2021-12-20 | ||
| PCT/EP2022/064995 WO2022253936A1 (en) | 2021-06-04 | 2022-06-02 | Triazine derivatives and their use in the treatment of cancer. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240928A1 true PE20240928A1 (es) | 2024-04-30 |
Family
ID=82115763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003133A PE20240928A1 (es) | 2021-06-04 | 2022-06-02 | Derivados de triazina y su uso en el tratamiento del cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20240132471A1 (es) |
| EP (1) | EP4347571A1 (es) |
| JP (2) | JP7705963B2 (es) |
| KR (1) | KR20240019083A (es) |
| AR (1) | AR126053A1 (es) |
| AU (1) | AU2022287224A1 (es) |
| BR (1) | BR112023025318A2 (es) |
| CA (1) | CA3216026A1 (es) |
| CL (1) | CL2023003491A1 (es) |
| CO (1) | CO2023016212A2 (es) |
| CR (1) | CR20230566A (es) |
| IL (1) | IL307201A (es) |
| MX (1) | MX2023013998A (es) |
| PE (1) | PE20240928A1 (es) |
| TW (1) | TW202313577A (es) |
| WO (1) | WO2022253936A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| EP4345097A4 (en) * | 2021-04-28 | 2025-04-23 | Astellas Pharma Inc. | SUBSTITUTED TRIAZINE COMPOUND |
| EP4461729A1 (en) * | 2022-01-07 | 2024-11-13 | Transthera Sciences (Nanjing), Inc. | Antigen binding protein targeting msln and use thereof |
| EP4558499A1 (en) * | 2022-07-21 | 2025-05-28 | F. Hoffmann-La Roche AG | Nlrp3 inhibitors |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| IL320499A (en) * | 2022-11-04 | 2025-06-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and use thereof |
| EP4630417A1 (en) * | 2022-12-07 | 2025-10-15 | F. Hoffmann-La Roche AG | Novel compounds as modulators of nlrp3 inhibition |
| AR132166A1 (es) * | 2023-03-20 | 2025-05-28 | Insilico Medicine Ip Ltd | Inhibidores de inflamasoma nlrp3 y usos de los mismos |
| AU2024240851A1 (en) * | 2023-03-23 | 2025-10-16 | Chengdu Zenitar Biomedical Technology Co., Ltd. | Triazine compound and use thereof |
| AR132455A1 (es) * | 2023-04-19 | 2025-07-02 | Hoffmann La Roche | Compuestos novedosos |
| CR20250409A (es) * | 2023-04-19 | 2025-10-30 | Hoffmann La Roche | Derivados de oxazolo[4,5-b]pirazina y oxazolo[4,5-b]piridina como inhibidores de nlpr3 para el tratamiento de, por ejemplo, enfermedades inflamatoria |
| WO2024249539A1 (en) | 2023-06-02 | 2024-12-05 | Merck Sharp & Dohme Llc | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| WO2025026882A1 (en) * | 2023-07-28 | 2025-02-06 | F. Hoffmann-La Roche Ag | Novel compounds |
| WO2025046419A1 (ko) * | 2023-08-25 | 2025-03-06 | 제일약품주식회사 | Nlrp3 저해제로서의 신규한 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025252772A1 (en) * | 2024-06-06 | 2025-12-11 | F. Hoffmann-La Roche Ag | Triazine derivatives |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| MA50567A (fr) | 2017-11-09 | 2020-09-16 | Inflazome Ltd | Nouveaux composés de sulfonamide carboxamide |
| JP7555327B2 (ja) | 2018-07-25 | 2024-09-24 | ノバルティス アーゲー | Ｎｌｒｐ３インフラマソーム阻害剤 |
| CN114007614A (zh) | 2019-02-04 | 2022-02-01 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| CN115461120A (zh) | 2020-01-22 | 2022-12-09 | 豪夫迈·罗氏有限公司 | 作为nlrp3调节剂的磺酰亚胺酰胺化合物 |
| US20230107277A1 (en) | 2020-03-27 | 2023-04-06 | Astellas Pharma Inc. | Substituted pyridazine compound |
| TW202231281A (zh) | 2020-12-25 | 2022-08-16 | 大陸商上海拓界生物醫藥科技有限公司 | 一類含噠嗪的化合物及其醫藥用途 |
| US20240166610A1 (en) | 2021-02-08 | 2024-05-23 | Medshine Discovery Inc. | Substituted pyridazine phenol derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| EP4345097A4 (en) | 2021-04-28 | 2025-04-23 | Astellas Pharma Inc. | SUBSTITUTED TRIAZINE COMPOUND |
| US20240294542A1 (en) | 2021-06-05 | 2024-09-05 | Transthera Sciences (Nanjing), Inc. | Nlrp3 inflammasome inhibitor and application thereof |
| WO2023275366A1 (en) | 2021-07-02 | 2023-01-05 | Astrazeneca Ab | Nlrp3 inflammasome inhibitors |
| WO2023028536A1 (en) | 2021-08-25 | 2023-03-02 | Ptc Therapeutics, Inc. | 1,2,4-triazine derivatives useful as inhibitors of nlrp3 |
| EP4421068A1 (en) | 2021-10-22 | 2024-08-28 | Zhejiang Aixplorer Biotech Co., Ltd. | Nitrogen-containing compound, preparation method therefor and application thereof |
| EP4461729A1 (en) | 2022-01-07 | 2024-11-13 | Transthera Sciences (Nanjing), Inc. | Antigen binding protein targeting msln and use thereof |
| JP2025510414A (ja) | 2022-03-25 | 2025-04-14 | ヴェンタス・セラピューティクス・ユー・エス・インコーポレイテッド | ＮＬＲＰ３誘導体として有用なピリド－［３，４－ｄ］ピリダジンアミン誘導体 |
| WO2024090469A1 (ja) | 2022-10-26 | 2024-05-02 | アステラス製薬株式会社 | 縮環ピリダジン誘導体 |
| CN115621720A (zh) * | 2022-10-27 | 2023-01-17 | 永道射频技术股份有限公司 | 一种应用于rfid读写器的全息超材料阵列天线 |
| IL320499A (en) | 2022-11-04 | 2025-06-01 | Transthera Sciences Nanjing Inc | Nlrp3 inflammasome inhibitor and use thereof |
| TW202440107A (zh) | 2022-12-28 | 2024-10-16 | 瑞典商阿斯特捷利康公司 | Ｎｌｒｐ３炎症小體抑制劑 |
| CN120435466A (zh) | 2023-02-17 | 2025-08-05 | 成都赜灵生物医药科技有限公司 | 六元氮杂环类化合物及其用途 |
-
2022
- 2022-06-02 WO PCT/EP2022/064995 patent/WO2022253936A1/en not_active Ceased
- 2022-06-02 EP EP22731614.8A patent/EP4347571A1/en active Pending
- 2022-06-02 TW TW111120574A patent/TW202313577A/zh unknown
- 2022-06-02 AR ARP220101456A patent/AR126053A1/es unknown
- 2022-06-02 KR KR1020237039328A patent/KR20240019083A/ko active Pending
- 2022-06-02 JP JP2023572751A patent/JP7705963B2/ja active Active
- 2022-06-02 CA CA3216026A patent/CA3216026A1/en active Pending
- 2022-06-02 BR BR112023025318A patent/BR112023025318A2/pt unknown
- 2022-06-02 AU AU2022287224A patent/AU2022287224A1/en active Pending
- 2022-06-02 CR CR20230566A patent/CR20230566A/es unknown
- 2022-06-02 IL IL307201A patent/IL307201A/en unknown
- 2022-06-02 MX MX2023013998A patent/MX2023013998A/es unknown
- 2022-06-02 PE PE2023003133A patent/PE20240928A1/es unknown
-
2023
- 2023-11-23 CL CL2023003491A patent/CL2023003491A1/es unknown
- 2023-11-29 CO CONC2023/0016212A patent/CO2023016212A2/es unknown
- 2023-11-30 US US18/524,678 patent/US20240132471A1/en not_active Abandoned
-
2025
- 2025-02-25 US US19/063,141 patent/US12421209B2/en active Active
- 2025-03-26 JP JP2025051003A patent/JP2025098157A/ja active Pending
- 2025-05-16 US US19/210,925 patent/US20250276958A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025098157A (ja) | 2025-07-01 |
| US20250197370A1 (en) | 2025-06-19 |
| MX2023013998A (es) | 2023-12-11 |
| US20240132471A1 (en) | 2024-04-25 |
| EP4347571A1 (en) | 2024-04-10 |
| TW202313577A (zh) | 2023-04-01 |
| CL2023003491A1 (es) | 2024-05-24 |
| BR112023025318A2 (pt) | 2024-02-27 |
| US12421209B2 (en) | 2025-09-23 |
| IL307201A (en) | 2023-11-01 |
| CR20230566A (es) | 2024-01-22 |
| WO2022253936A1 (en) | 2022-12-08 |
| AR126053A1 (es) | 2023-09-06 |
| JP2024522494A (ja) | 2024-06-21 |
| US20250276958A1 (en) | 2025-09-04 |
| JP7705963B2 (ja) | 2025-07-10 |
| CO2023016212A2 (es) | 2023-12-11 |
| AU2022287224A1 (en) | 2023-09-21 |
| CA3216026A1 (en) | 2022-12-08 |
| KR20240019083A (ko) | 2024-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240928A1 (es) | Derivados de triazina y su uso en el tratamiento del cancer | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| AR123048A2 (es) | Moduladores de p2x7 | |
| MX2019011679A (es) | Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular. | |
| UY37854A (es) | Derivados de 3- (1-oxoisoindolin-2-il) piperidina-2,6-diona y usos de los mismos | |
| AR116109A1 (es) | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos | |
| CO6251294A2 (es) | Derivados de 9-(pirazol-3-il)-9h-purin-2-amina y 3-(pirazol-3-il)-3h-imidazol4,5-b piridin-5-amina y su uso para el tratamiento del cancer | |
| PE20211781A1 (es) | Inhibidores de la replicacion del virus de la inmunodeficiencia humana | |
| PE20160608A1 (es) | Compuestos de quinolina selectivamente sustituida | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| ECSP22027871A (es) | COMPUESTOS HETEROC?CLICOS DE ARILMETILENO COMO BLOQUEADORES DEL CANAL SHAKER DE POTASIO Kv1.3 | |
| AR108778A1 (es) | Compuestos antibacterianos | |
| CL2024001620A1 (es) | Inhibidores del sarcómero cardíaco | |
| PE20171335A1 (es) | Inhibidores de gingipaina de lisina | |
| CU20210023A7 (es) | Inhibidores fenil sustituidos de la piridinil 1,2-oxaborolan-2-ol fosfodiesterasa 4 | |
| CL2020003380A1 (es) | Compuestos que aumentan la actividad del proteosoma. | |
| CL2025001372A1 (es) | Derivados de triazinona como inhibidores de nlrp3. | |
| AR083861A1 (es) | OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN | |
| CL2024001481A1 (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| MX2024012471A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| CO2025003256A2 (es) | Derivados novedosos deuterados de pirimidin-2-il sulfonamida | |
| CL2025000126A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CL2025000125A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CL2023003921A1 (es) | Inhibidores de transglutaminasas | |
| UY37641A (es) | Compuestos de isoxazol carboxamida y usos de los mismos |